Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 4/20 | 0.32 |
| ▸ | LPL | P06858 | 1/20 | 0.30 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26921895 | 0.83 | ADRA2A (0.37) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL15158988 | 0.79 | LPL (0.37) | LPLLIPG | |
| SCHEMBL15230780 | 0.78 | MAPT (0.41) | EGFRLPLLIPG | |
| SCHEMBL26921621 | 0.77 | ALDH1A1 (0.37) | — | |
| SCHEMBL21653672 | 0.76 | PTPN11 (0.34) | — | |
| SCHEMBL21631467 | 0.76 | PTPN11 (0.38) | EGFR | |
| SCHEMBL29467494 | 0.76 | PTPN11 (0.34) | — | |
| SCHEMBL21653799 | 0.76 | JAK2 (0.30) | — | |
| SCHEMBL20894750 | 0.73 | LPL (0.33) | EGFRLPLLIPG | |
| SCHEMBL29537987 | 0.73 | LPL (0.33) | EGFRLPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240101577-A1 | POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. | 2024-03-28 | — | — | US | disclosed |
| CN-111433205-B | Polycyclic compounds as allosteric SHP2 inhibitors | 锐新医药公司 | 2024-01-19 | — | — | CN | disclosed |
| EP-3724189-B1 | POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | REVOLUTION MEDICINES INC (US) | 2023-10-04 | — | — | EP | disclosed |
| US-11673901-B2 | Polycyclic compounds as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11634435-B2 | — | — | 2023-04-25 | — | — | US | disclosed |
| US-20200407372-A1 | POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. | 2020-12-31 | — | — | US | disclosed |
| EP-3724189-A1 | POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. (US) | 2020-10-21 | — | — | EP | disclosed |
| CN-111433205-A | Polycyclic compounds as allosteric SHP2 inhibitors | 锐新医药公司 | 2020-07-17 | — | — | CN | disclosed |
| WO-2019118909-A1 | POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. (US) | 2019-06-20 | — | — | WO | disclosed |
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-22 | — | — | US | disclosed |
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-22 | — | — | US | disclosed |
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-22 | — | — | US | disclosed |
| WO-2010020363-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673901-B2 | Polycyclic compounds as allosteric SHP2 inhibitors | PTPN18, PTPN1, PTPRJ | ADRA2A 4681/4885ADRA2B 4598/4885ADRA2C 4530/4885 |
| US-20240101577-A1 | POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | PTPN18, PTPN1, PTPRJ | ADRA2A 4681/4885ADRA2B 4598/4885ADRA2C 4530/4885 |
| US-11634435-B2 | — | PTPN18, PTPN6, PTPN5 | ADRA2A 4598/4885ADRA2B 4432/4885ADRA2C 4543/4885 |
| US-20200407372-A1 | POLYCYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | PTPN18, PTPN1, PTPRJ | ADRA2A 4681/4885ADRA2B 4598/4885ADRA2C 4530/4885 |
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | CYP3A5, ABAT, TPMT | ADRA2A 1144/4885ADRA2B 579/4885ADRA2C 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.